{"id":"https://openalex.org/W2760414622","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.7593","title":"Pharmacokinetics (PK) and exposure-response (ER) of rilotumumab (Rmab) in patients (pts) with small-cell lung cancer (SCLC).","display_name":"Pharmacokinetics (PK) and exposure-response (ER) of rilotumumab (Rmab) in patients (pts) with small-cell lung cancer (SCLC).","publication_year":2014,"publication_date":"2014-05-20","ids":{"openalex":"https://openalex.org/W2760414622","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.7593","mag":"2760414622"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2014.32.15_suppl.7593","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.7593","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.7593","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100618235","display_name":"Yilong Zhang","orcid":"https://orcid.org/0000-0001-6750-7613","observed_orcids":["https://orcid.org/0000-0001-6750-7613"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yilong Zhang","raw_affiliation_strings":["Amgen, Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen, Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104110470","display_name":"Jenny Zheng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jenny Zheng","raw_affiliation_strings":["Pfizer, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Inc., San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Rui Tang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rui Tang","raw_affiliation_strings":["Biostatistics \u2013 Medical Sciences, Amgen, Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics \u2013 Medical Sciences, Amgen, Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112904823","display_name":"Elwyn Y. Loh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elwyn Loh","raw_affiliation_strings":["Amgen, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110784387","display_name":"Sarita Dubey","orcid":"https://orcid.org/0009-0004-7635-0530","observed_orcids":["https://orcid.org/0009-0004-7635-0530"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarita Dubey","raw_affiliation_strings":["Amgen, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100708185","display_name":"Min Zhu","orcid":"https://orcid.org/0000-0002-5669-9602","observed_orcids":["https://orcid.org/0000-0002-5669-9602"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Min Zhu","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"32","issue":"15_suppl","first_page":"7593","last_page":"7593"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.9247999787330627,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.9247999787330627,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.013100000098347664,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.01080000028014183,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rilotumumab","display_name":"rilotumumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/small-cell-lung-cancer","display_name":"small cell lung cancer","score":0.9670000076293945},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8730000257492065},{"id":"https://openalex.org/keywords/exposure-response-relationship","display_name":"exposure-response relationship","score":0.8740000128746033},{"id":"https://openalex.org/keywords/hepatocyte-growth-factor","display_name":"hepatocyte growth factor","score":0.9100000262260437},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.800000011920929},{"id":"https://openalex.org/keywords/extensive-stage-small-cell-lung-cancer","display_name":"extensive-stage small cell lung cancer","score":0.8169999718666077},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.609000027179718},{"id":"https://openalex.org/keywords/etoposide","display_name":"etoposide","score":0.6650000214576721},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.9660000205039978},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.9670000076293945},{"id":"https://openalex.org/keywords/tumor-size","display_name":"tumor size","score":0.4339999854564667},{"id":"https://openalex.org/keywords/survival-analysis","display_name":"survival analysis","score":0.4620000123977661},{"id":"https://openalex.org/keywords/body-weight-effects","display_name":"body weight effects","score":0.5389999747276306},{"id":"https://openalex.org/keywords/trough-concentration","display_name":"trough concentration","score":0.7929999828338623}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8306124806404114},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.6424949169158936},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5719517469406128},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5325198769569397},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5079405903816223},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.49769213795661926},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4969680607318878},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.45321741700172424},{"id":"https://openalex.org/C2778119113","wikidata":"https://www.wikidata.org/wiki/Q418817","display_name":"Etoposide","level":3,"score":0.4508306384086609},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.4315243065357208},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.40699824690818787},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.30731090903282166},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.17179661989212036},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2014.32.15_suppl.7593","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.7593","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.7593","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2590733322","https://openalex.org/W4414128390","https://openalex.org/W7207935104","https://openalex.org/W4285587076","https://openalex.org/W2799800730","https://openalex.org/W4200029654","https://openalex.org/W7212019266","https://openalex.org/W7213274570","https://openalex.org/W4396704371","https://openalex.org/W2612259296"],"abstract_inverted_index":{"7593":[0],"Background:":[1],"Rmab":[2,49,71,91,192,216,255,272,307,322,353],"is":[3,344],"a":[4,17,24,125,222,238,269,348,355],"fully":[5],"human":[6],"monoclonal":[7],"antibody":[8],"against":[9],"hepatocyte":[10],"growth":[11,133],"factor":[12],"that":[13,60,299],"was":[14,107,122,218,265,315,324],"evaluated":[15,172],"as":[16],"first-line":[18],"treatment":[19],"for":[20],"extensive-stage":[21],"SCLC":[22,54,83],"in":[23,39,51,79,241,278,288,329],"phase":[25,112,116],"1b/2":[26],"trial":[27,33],"(J":[28],"Thorac":[29],"Oncol.":[30],"2013;8(S2):O21.05).":[31],"That":[32],"did":[34,256],"not":[35,257,287],"show":[36],"meaningful":[37],"improvements":[38],"progression-free":[40],"survival":[41,45,179],"(PFS)":[42],"or":[43,94,145],"overall":[44],"(OS).":[46],"We":[47],"characterized":[48,123,220],"PK":[50,62,73,217,224],"pts":[52,81],"with":[53,82,96,203,213,326],"and":[55,68,75,114,129,135,161,167,177,186,205,207,232,247,311,346,352],"performed":[56,202,212],"an":[57,259],"ER":[58,76,331],"analysis":[59,297],"related":[61],"to":[63,88,131,148,276,339,362],"tumor":[64,126,132,168,208],"size":[65],"(TS),":[66],"PFS,":[67],"OS.":[69,364],"Methods:":[70],"population":[72],"(PPK)":[74],"were":[77,85,152,171,182,201,211],"assessed":[78],"132":[80],"who":[84],"randomized":[86],"1:1":[87],"receive":[89],"either":[90],"(15":[92],"mg/kg)":[93],"placebo,":[95],"etoposide":[97],"plus":[98],"carboplatin/cisplatin":[99],"every":[100],"3":[101],"weeks":[102,147],"(Q3W).":[103],"A":[104],"PPK":[105,206],"model":[106],"developed":[108],"using":[109,124,173],"data":[110],"from":[111,154],"1":[113],"earlier":[115],"2":[117],"studies.":[118],"TS":[119,136,141,149],"vs":[120],"time":[121,130],"dynamic":[127,209],"model,":[128],"(TTG)":[134],"ratios":[137,139],"(the":[138],"of":[140,235,303,350],"at":[142,150,195,354],"6,":[143],"9,":[144],"12":[146],"baseline)":[151],"derived":[153],"this":[155,330,342],"model.":[156,225],"The":[157],"relationships":[158],"between":[159],"PFS/OS":[160],"baseline":[162],"pt":[163],"characteristics,":[164],"exposure":[165,323],"metrics,":[166],"response":[169],"metrics":[170],"Cox":[174],"proportional":[175],"hazards":[176],"parametric":[178],"models.":[180],"Pts":[181],"divided":[183],"into":[184],"high-":[185],"low-exposure":[187,290],"groups":[188],"based":[189],"on":[190,262],"median":[191],"trough":[193],"concentration":[194],"steady":[196],"state":[197],"(Cminss).":[198],"Survival":[199],"analyses":[200,210],"R,":[204],"NONMEM.":[214],"Results:":[215],"well":[219],"by":[221,245,249,268],"two-compartment":[223],"Body":[226],"weight":[227],"(WT)":[228],"affected":[229],"clearance":[230],"(CL)":[231],"central":[233],"volume":[234],"distribution":[236],"(Vc):":[237],"10%":[239],"increase":[240],"WT":[242],"increased":[243],"CL":[244],"6%":[246],"Vc":[248],"7%.":[250],"Chemotherapy":[251],"reduced":[252],"TS,":[253],"but":[254,286,333],"have":[258],"additional":[260],"effect":[261],"TS.":[263],"OS":[264,274,304,328],"best":[266],"described":[267],"log-logistic":[270],"distribution.":[271],"improved":[273,327,363],"relative":[275],"placebo":[277],"the":[279,289],"high-exposure":[280],"group":[281,291],"(Cminss":[282,292],">":[283,357],"155":[284,294],"mg/mL)":[285],"\u2264":[293],"mg/mL).":[295],"Univariate":[296],"suggested":[298],"favorable":[300],"predictive":[301],"factors":[302],"included":[305],"higher":[306],"exposure,":[308],"female":[309],"sex,":[310],"longer":[312],"TTG.":[313],"There":[314],"no":[316],"apparent":[317],"PK-PFS":[318],"relationship.":[319],"Conclusions:":[320],"High":[321],"associated":[325],"analysis,":[332],"further":[334],"studies":[335],"will":[336],"be":[337],"needed":[338],"determine":[340],"whether":[341,347],"association":[343],"causative":[345],"combination":[349],"chemotherapy":[351],"dose":[356],"15":[358],"mg/kg":[359],"Q3W":[360],"leads":[361]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2017-10-06T00:00:00"}